Evidence map›Paper›PMID 36354442›Full record

ArticleBiosensors2022

The Current Status and Future Promise of SPR Biosensors.

Nan-Fu Chiu

Abstract readEditorial
In one paragraph

Article in Biosensors, 2022. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 11 papers.

0numbers the graph read from it
0cells of the map it votes in
11citing papers in PubMed
–field-weighted citation impact
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

11 citing papers in PubMed.

  1. Journal of pharmaceutical analysis · 2026
    Article
  2. Article
  3. Article
  4. Article
  5. Article
  6. Review
  7. Review
  8. Review
  9. Review
  10. Review
  11. Review
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

1 author.

Nan-Fu ChiuLaboratory of Nano-Photonics and Biosensors, Institute and Undergraduate of Electro-Optical Engineering, National Taiwan Normal University, Taipei 11677, Taiwan.ORCID 0000-0003-1995-5483

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

The most commonly used protein detection methods in clinical diagnosis and disease monitoring are enzyme-linked immunosorbent assay (ELISA), Western blotting (immunoblot), and lateral flow assay (LFA) rapid screening, of which ELISA is the gold standard immunoassay in clinical practice [...].

Indexed as

Biosensing TechniquesSurface Plasmon ResonanceEnzyme-Linked Immunosorbent AssayImmunoassay

Identifiers

PMID36354442
PMCPMC9687760

What OpenQuestion holds

Textmetadata
LicenceCC BY
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.